Axis-Shield Ltd Stock

Equities

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-.--%	-.--%

Duration

Period

Style

Axis Shield : The Effect of Food Intake on the Pharmacokinetics of Vadadustat Following Single Dose Administration	20-07-29	PU
Axis Shield : Randomized, Double-Blinded, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat in Chronic Kidney Disease Patients With Anemia on Hemodialysis in Japan	20-07-29	PU
Axis Shield : Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia	20-07-29	PU
Axis Shield : Targeted Literature Review of Patient-reported Burden of Anemia in Chronic Kidney Disease	20-07-29	PU
Efficacy and Safety of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Being Evaluated for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Japanese Subjects: Results from Phase 2 Studies (encore)	20-07-29	PU

Axis-Shield Ltd is a United Kingdom-based company. The Company develops, manufactures and markets in-vitro diagnostic products.

Sector

	1st Jan change	Capi.
AXIS-SHIELD LTD	-.--%	0
BIOMÉRIEUX	-4.52%	12.39B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.60%	8.43B
DIASORIN S.P.A.	+6.56%	5.77B
LANTHEUS HOLDINGS, INC.	+32.69%	5.76B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.21%	4.1B
ANDON HEALTH CO., LTD.	+10.62%	2.66B
10X GENOMICS, INC.	-61.22%	2.66B
VITROLIFE AB	-7.81%	2.39B
MYRIAD GENETICS, INC.	+17.71%	2.02B